

To,

Date: 24/01/2018

- 1) BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
- 2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E), Mumbai – 400 098
- 3) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanand College,
Panjara Pole, Ambawadi, Ahmedabad – 380 015

Sub: Outcome of Board Meeting under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Company's Letter dated Wednesday, 17th January, 2018


Further to our above referred letter, this is to inform Exchange that the Board of Directors of the Company at its meeting held today i.e., Wednesday, the 24th day of January, 2018 at Registered Office, have approved and taken on record the following:

1. Standalone Unaudited Financial Results for **Quarter III and 9 Months Ended 31st December, 2017** along with Limited Review Report issued by Statutory Auditors in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.
2. Allotment of 10,00,000 Convertible Equity Share Warrants on Preferential Basis to Promoters of the Company; upon receiving of In-principle approvals BSE Limited on, 08th January, 2018 and Metropolitan Stock Exchange of India Limited on 10th January, 2018.

S. No.	Name of the Allottees	Convertible Equity Share Warrants
1	Dr. Mohammed Aejaz Habeeb	5,00,000
2	Dr. Syed Ameer Basha Paspala	5,00,000
TOTAL		10,00,000

3. Allotment of 7,00,000 Equity Shares, pursuant to Conversion of 7,00,000 Convertible Equity Share Warrants to the Non-Promoters of the Company.

S. No.	Name of the Allottees	Equity Shares
1	Mr. M. Srinivas Chaitanya	3,00,000
2	Ms. Nikita Korupolu	3,00,000
3	Mr. Ravi Mandava	1,00,000
TOTAL		7,00,000



Dr Habeebullah Life Sciences Ltd

Regd.Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India
Corp.Off : No.II, Phase I, Vasudeva Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008. TS.India
CIN No. : L85110TG1996PLC099198
Contact No.: 040 - 2970 3333, +91 9030057370

Email : pcproductsindia@gmail.com

Website : www.drhlsl.com

(Formerly Known as PC Products India Ltd.)

The meeting commenced at 3.00 PM and concluded at 5.00 PM.

Request you take the same on records.

Thanking you.

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)



Encl: as above

PART-I		(Rupees in Lacs)				
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2017						
S.No	Particulars	QUARTER ENDED			NINE MONTHS ENDED	
		3 Months ended 31-12-2017	Preceding 3 months ended 30-9-2017	Corresponding 3 months ended in previous year 31-12-2016	Year to date figures for the current period ended 31-12-2017	Year to date figures for the previous year ended 31-12-2016
		UnAudited	Unaudited	UnAudited	UnAudited	Unaudited
I	Revenue from Operations	20.12	14.95	12.91	37.62	123.83
II	Other Income	0	0	0	0	1.21
III	Total Revenue (I+II)	20.12	14.95	12.91	37.62	125.04
IV	Expenses					
	Cost of Material Consumed	1.31	0.56	0	1.87	0
	Purchase of Stock-in-trade	0	0	11.43	0	120.17
	Changes in inventories of finished goods, Work in progress and Stock in trade	0	0	0	0	0
	Employee Costs	18.26	16.64	1.20	57.09	4.00
	Employee benefits expense	0.99	1.18	0.00	2.17	0.00
	Finance Costs	0	0	0	0	0
	Depreciation and Amortisation expense	0	0	0	0	0
	Other Expense	25.63	6.28	10.20	42.90	16.90
	Total Expenses	46.19	24.66	22.83	104.03	141.07
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	-26.07	-9.71	-9.92	-66.41	-16.03
VI	Exceptional Items					
VII	Profit/(Loss) before tax (V-VI)	-26.07	-9.71	-9.92	-66.41	-16.03
VIII	Tax Expense:					
	Current Tax	0	0	0	0	0
	Deferred Tax	0	0	0	0	0
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	-26.07	-9.71	-9.92	-66.41	-16.03
X	Profit/ (Loss) from discontinuing operations	0	0	0	0	0
XI	Tax Expense of discontinuing operations	0	0	0	0	0
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	0	0	0	0	0
XIII	Profit/ (Loss) for the period (IX+XII)	-26.07	-9.71	-9.92	-66.41	-16.03
XIV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	0	0	0	0	0
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	-26.07	-9.71	-9.92	-66.41	-16.03
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	-0.23	-0.09	-0.09	-0.60	-0.15
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	0	0	0	0	0
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each) 1) Basic 2) Diluted	-0.23	-0.09	-0.09	-0.60	-0.15
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1105.87	1025.87	1025.87	1105.87	1025.87



Dr Habeebullah Life Sciences Ltd

Regd.Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India
Corp.Off : No.II, Phase I, Vasudeva Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008. TS.India
CIN No. : L85110TG1996PLC099198 Email : pcproductsindia@gmail.com
Contact No.: 040 - 2970 3333, +91 9030057370 Website : www.drhlsl.com

(Formerly Known as PC Products India Ltd.)


Notes:

- 1A Beginning April, 2017; the Company has for the first time adopted the Indian Accounting Standards (Ind AS) with a transition date of April, 2016 and accordingly these financial statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder.
- 1B The format for the Standalone Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed. Hence, Figures of Previous Year Ended 31st March, 2017 have not been provided.
- 2 During the Quarter, the Company has allotted 8,00,000 Equity Shares and 27,50,000 Convertible Warrants to Non-Promoters of the Company.
- 3 The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- 4 **During the Quarter III, the Company has filed 1 Patent - Bioengineered Humanized Endocrine Neo-Organ using Decellularized Spleen Matrices.**
- 5 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on **Wednesday 24th January, 2018.**
- 6 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors of the Company. The Ind AS Complaint figures for the Corresponding previous Quarter ended 31st December, 2016 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 7 Reconciliation of Net Profit reported under Indian GAAP for the Quarter III and 9 Months Ended 31st December 2016 with Ind AS is furnished below:

Particulars	Quarter Ended 31/12/2016 (Rs. In Lacs)	9 Months Ended 31/12/2016 (Rs. In Lacs)
Net Profit as per previous GAAP	-9.92	-16.03
Increase in profit due to:		
Fair Value Impact for financial instrument	NIL	NIL
Net Profit after Ind AS (After Tax)	-9.92	-16.03
Other Comprehensive Income	NIL	NIL
Total Comprehensive Income under Ind AS	-9.92	-16.03

- 9 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 10 The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad
Date : 24/01/2018



For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)

Dr Habeebullah Life Sciences Ltd

Regd.Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India
 Corp.Off : No.II, Phase I, Vasudeva Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008. TS.India
 CIN No. : L85110TG1996PLC099198 Email : peproductsindia@gmail.com
 Contact No.: 040 - 2970 3333, +91 9030057370 Website : www.drhlsl.com

(Formerly Known as PC Products India Ltd.)



N. M. KHATAVKAR & CO.
CHARTERED ACCOUNTANTS

Cell : 94488 37388
Tele / Fax : 0836 2258841
Email : nandrajkhatavkar@yahoo.com
nmk1365@gmail.com

LIMITED REVIEW REPORT

(Standalone Unaudited Financial Results – As per Reg. 33 of SEBI [LODR] Regulations, 2015)

Review Report to DR HABEEBULLAH LIFE SCIENCES LIMITED, Hyderabad.

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of DR HABEEBULLAH LIFE SCIENCES LIMITED (Formerly Known as PC Products India Limited) for the **Period/Quarter III and 9 Months Ended 31st December, 2017**. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been compiled from the related financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) (as amended), prescribed under Section 133 of the Companies Act, 2013 read together with relevant applicable rules issued there under; or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statements based on our audit of such standalone financial statements.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Unaudited Financial Results prepared in accordance with applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016; including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hubli
Date: 24/01/2018

For N.M.Khatavkar & Co.,
Chartered Accountants



N.M.Khatavkar
Proprietor
Membership No. 206569
Firm Regd No. 0079395

Divate Complex, Club Road, Hubli - 580029.